Review





Similar Products

inc  (Developmental Studies Hybridoma Bank)
99
Developmental Studies Hybridoma Bank inc
Inc, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inc/product/Developmental Studies Hybridoma Bank
Average 99 stars, based on 1 article reviews
inc - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
inc g actin f actin  (Cytoskeleton Inc)
97
Cytoskeleton Inc inc g actin f actin
Inc G Actin F Actin, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inc g actin f actin/product/Cytoskeleton Inc
Average 97 stars, based on 1 article reviews
inc g actin f actin - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
inc mouse monoclonal antibodies against mtor  (Proteintech)
96
Proteintech inc mouse monoclonal antibodies against mtor
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Inc Mouse Monoclonal Antibodies Against Mtor, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inc mouse monoclonal antibodies against mtor/product/Proteintech
Average 96 stars, based on 1 article reviews
inc mouse monoclonal antibodies against mtor - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
ha trap nanobody agarose beads lablead inc cat  (Thermo Fisher)
99
Thermo Fisher ha trap nanobody agarose beads lablead inc cat
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Ha Trap Nanobody Agarose Beads Lablead Inc Cat, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ha trap nanobody agarose beads lablead inc cat/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
ha trap nanobody agarose beads lablead inc cat - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
133 inc  (Cell Applications Inc)
95
Cell Applications Inc 133 inc
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
133 Inc, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/133 inc/product/Cell Applications Inc
Average 95 stars, based on 1 article reviews
133 inc - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
talon metal affinity resin takara bio inc  (TaKaRa)
99
TaKaRa talon metal affinity resin takara bio inc
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Talon Metal Affinity Resin Takara Bio Inc, supplied by TaKaRa, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/talon metal affinity resin takara bio inc/product/TaKaRa
Average 99 stars, based on 1 article reviews
talon metal affinity resin takara bio inc - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
inc cat  (InvivoGen)
97
InvivoGen inc cat
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Inc Cat, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/inc cat/product/InvivoGen
Average 97 stars, based on 1 article reviews
inc cat - by Bioz Stars, 2026-02
97/100 stars
  Buy from Supplier
glycol 5000 880200p avanti polar lipids inc  (Croda International Plc)
94
Croda International Plc glycol 5000 880200p avanti polar lipids inc
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Glycol 5000 880200p Avanti Polar Lipids Inc, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glycol 5000 880200p avanti polar lipids inc/product/Croda International Plc
Average 94 stars, based on 1 article reviews
glycol 5000 880200p avanti polar lipids inc - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
cea448mu rnaiso plus takara bio inc  (TaKaRa)
99
TaKaRa cea448mu rnaiso plus takara bio inc
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Cea448mu Rnaiso Plus Takara Bio Inc, supplied by TaKaRa, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cea448mu rnaiso plus takara bio inc/product/TaKaRa
Average 99 stars, based on 1 article reviews
cea448mu rnaiso plus takara bio inc - by Bioz Stars, 2026-02
99/100 stars
  Buy from Supplier
glycol 2000 880160p avanti polar lipids inc  (Croda International Plc)
94
Croda International Plc glycol 2000 880160p avanti polar lipids inc
<t>AKT/mTOR</t> pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.
Glycol 2000 880160p Avanti Polar Lipids Inc, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glycol 2000 880160p avanti polar lipids inc/product/Croda International Plc
Average 94 stars, based on 1 article reviews
glycol 2000 880160p avanti polar lipids inc - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


AKT/mTOR pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.

Journal: Oncology Reports

Article Title: Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy

doi: 10.3892/or.2025.9033

Figure Lengend Snippet: AKT/mTOR pathway inhibition by GEM and SSD combination therapy. (A) Immunocytochemistry staining of AKT/mTOR signaling proteins in MIA PaCa-2 and AsPC-1 cells treated with Ctrl, G0.25, S4 or the combination (G0.25 + S4; magnification, ×40; insets show phosphoprotein details). Scale bar, 50 µm. (B) Western blot analysis of p-AKT (60 kDa), AKT (56 kDa), p-mTOR (289 kDa), mTOR (289 kDa) and β-actin (42 kDa). Semi-quantification of phosphorylation ratios in (C) MIA PaCa-2 and (D) AsPC-1 cells. In the figure, GEM represents 0.25 µmol/l GEM and SSD represents 4 µmol/l SSD. Data are presented as the mean ± SD (n=5). Compared with GEM monotherapy, the G0.25 + S4 combination led to a greater reduction in both p-AKT/AKT and p-mTOR/mTOR ratios (both P adj <0.0001), with large effect sizes (η 2 =0.73 and 0.81, respectively). All P-values are Benjamini-Hochberg-adjusted. ****P<0.0001 for G0.25 + S4 vs. Ctrl; ## P<0.01, ### P<0.001 for G0.25 + S4 vs. G0.25. Statistical analysis was performed using one-way ANOVA with Tukey's post hoc test. Ctrl, control; GEM, gemcitabine; SSD, Saikosaponin D; p-, phosphorylated.

Article Snippet: The following antibodies were purchased from Proteintech Group, Inc.: Mouse monoclonal antibodies against mTOR (1:500; cat. no. 66888-1-Ig), phosphorylated (p-)mTOR (Ser2448) (1:2,000; cat. no. 67778-1-Ig), p-AKT (Ser473) (1:500; cat. no. 66444-1-Ig), caspase-3 (1:2,000; cat. no. 66470-2-Ig), cleaved caspase-3 (1:1,000; cat. no. 66470-2-Ig), Bax (1:500; cat. no. 60267-1-Ig), AKT (1:500; cat. no. 60203-2-Ig) and β-actin (1:2,000; cat. no. 66009-1-Ig); as well as rabbit antibodies, including polyclonal antibodies against Bcl-2 (1:1,000; cat. no. 12789-1-AP), Beclin 1 (1:1,000; cat. no. 11306-1-AP) and LC3 (1:1,000; cat. no. 14600-1-AP).

Techniques: Inhibition, Immunocytochemistry, Staining, Western Blot, Phospho-proteomics, Control

Proposed mechanism of GEM and SSD combination therapy. Co-treatment with GEM and SSD synergistically inhibits the AKT/mTOR pathway, concurrently inducing apoptosis (via Bax/Bcl-2 modulation and caspase-3 activation) and autophagy (via Beclin 1 activation and LC3 conversion), thereby overcoming GEM resistance in pancreatic cancer cells. GEM, gemcitabine; P, phosphorylated; SSD, Saikosaponin D.

Journal: Oncology Reports

Article Title: Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy

doi: 10.3892/or.2025.9033

Figure Lengend Snippet: Proposed mechanism of GEM and SSD combination therapy. Co-treatment with GEM and SSD synergistically inhibits the AKT/mTOR pathway, concurrently inducing apoptosis (via Bax/Bcl-2 modulation and caspase-3 activation) and autophagy (via Beclin 1 activation and LC3 conversion), thereby overcoming GEM resistance in pancreatic cancer cells. GEM, gemcitabine; P, phosphorylated; SSD, Saikosaponin D.

Article Snippet: The following antibodies were purchased from Proteintech Group, Inc.: Mouse monoclonal antibodies against mTOR (1:500; cat. no. 66888-1-Ig), phosphorylated (p-)mTOR (Ser2448) (1:2,000; cat. no. 67778-1-Ig), p-AKT (Ser473) (1:500; cat. no. 66444-1-Ig), caspase-3 (1:2,000; cat. no. 66470-2-Ig), cleaved caspase-3 (1:1,000; cat. no. 66470-2-Ig), Bax (1:500; cat. no. 60267-1-Ig), AKT (1:500; cat. no. 60203-2-Ig) and β-actin (1:2,000; cat. no. 66009-1-Ig); as well as rabbit antibodies, including polyclonal antibodies against Bcl-2 (1:1,000; cat. no. 12789-1-AP), Beclin 1 (1:1,000; cat. no. 11306-1-AP) and LC3 (1:1,000; cat. no. 14600-1-AP).

Techniques: Activation Assay